PMV Pharmaceuticals, Inc.·4

Jan 22, 4:37 PM ET

Mack David Henry 4

4 · PMV Pharmaceuticals, Inc. · Filed Jan 22, 2025

Insider Transaction Report

Form 4
Period: 2024-12-03
Mack David Henry
DirectorPresident and CEO
Transactions
  • Exercise/Conversion

    Employee Stock Option (right to buy)

    2025-01-0317,7090 total
    Exercise: $0.53Exp: 2025-05-11Common Stock (17,709 underlying)
  • Exercise/Conversion

    Common Stock

    2024-12-03$0.53/sh+91,750$48,628534,210 total
  • Exercise/Conversion

    Employee Stock Option (right to buy)

    2024-12-0391,75017,709 total
    Exercise: $0.53Exp: 2025-05-11Common Stock (91,750 underlying)
  • Exercise/Conversion

    Common Stock

    2025-01-03$0.53/sh+17,709$9,386551,919 total
Holdings
  • Common Stock

    (indirect: See footnote)
    147,915
  • Common Stock

    (indirect: See footnote)
    165,307
  • Common Stock

    (indirect: See footnote)
    56,978
Footnotes (4)
  • [F1]The shares are held of record by the Stinson 2021 Irrevocable Trust. The reporting person disclaims beneficial ownership of these securities except to the extent of any pecuniary interest therein.
  • [F2]The shares are held of record by the Mack/Mulligan 2020 Irrevocable Descendants' Trust. The reporting person disclaims beneficial ownership of these securities except to the extent of any pecuniary interest therein.
  • [F3]The shares are held of record by the Mack/Mulligan 2020 Irrevocable Descendants' Trust. The reporting person disclaims beneficial ownership of these securities except to the extent of any pecuniary interest therein.
  • [F4]The shares subject to the option are fully vested and immediately exercisable.

Documents

1 file
  • 4
    form4-01222025_090129.xmlPrimary